Chutes & Ladders—Former Translate CMO Ann Barbier is moving to Camp4 Therapeutics in the same rolenews2022-03-17T19:51:57+00:00March 17th, 2022|FierceBiotech|
‘Stay alive’: Wave of layoffs crashes into biotech startup infernonews2022-03-17T16:35:40+00:00March 17th, 2022|FierceBiotech|
NIH squashes Synairgen’s COVID therapy from ACTIV-2 trial after omicron shakes up studynews2022-03-17T14:42:28+00:00March 17th, 2022|FierceBiotech|
Athenex cuts jobs, narrows focus to cell therapies in continued fallout from 2021 FDA rejectionnews2022-03-17T14:09:53+00:00March 17th, 2022|FierceBiotech|
Sensorion spins hearing loss flop into exploratory win in attempt to revive lead programnews2022-03-17T13:55:37+00:00March 17th, 2022|FierceBiotech|
Bridging the preclinical to clinical divide: practical considerations for biomarker successnews2022-03-17T13:29:49+00:00March 17th, 2022|FierceBiotech|
Silence stops enrollment in blood cancer arm of RNAi trial over ‘recruitment challenges’news2022-03-17T12:34:28+00:00March 17th, 2022|FierceBiotech|
AstraZeneca throws open doors to new ideas in global postdoc challengenews2022-03-17T10:36:23+00:00March 17th, 2022|FierceBiotech|
Eiger eager to send COVID-19 drug to FDA after hospitalizations, deaths slashed—including against omicronnews2022-03-16T18:53:10+00:00March 16th, 2022|FierceBiotech|
Shionogi’s COVID-19 antiviral heads to phase 3 backed by NIH after receiving FDA go-aheadnews2022-03-16T18:21:36+00:00March 16th, 2022|FierceBiotech|
